-
- October 2, 2018
- Distribution Agreement for Clenafin/Jublia in Hong Kong and Macau
-
- July 31, 2018
- Seikagaku and Kaken Announce the Launch of HERNICORE®1.25 Units for Intradiscal Injection in Japan,Indicated for Treatment of Lumbar Disc Herniation
-
- June 14, 2018
- TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in Taiwan
-
- May 22, 2018
- Seikagaku and Kaken Announce the Listing in the National Health Insurance Drug Price List and Launch Date of HERNICORE® 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation
-
- February 28, 2018
- Licensing Agreement for KP-470 with Valeant Pharmaceuticals
-
- November 8, 2017
- Distribution Agreement for Clenafin/Jublia in Taiwan
-
- June 13, 2017
- Collaboration Research Agreement for a multispecific antibody candidate with Numab
-
- May 31, 2017
- Launch of Jublia in Korea
-
- May 17, 2017
- Approval for sale of Jublia in Korea
-
- November 18, 2016
- The NHI Drug Reimbursement Price Listing and Launch of REGROTH® Dental Kit (600µg & 1200µg)
-
- September 28, 2016
- Domestic New Drug Application (NDA) Approval for REGROTH® Dental Kit (600µg & 1200µg)
-
- July 11, 2016
- Kyorin Pharmaceutical and Kaken Pharmaceutical signed a Contract for
the co-promotion of the anti-allergic therapeutic agent “desloratadine”
-
- May 31, 2016
- Distributing Agreement for Clenafin/Jublia in Korea
-
- April 26, 2016
- License agreement for MediWound’s NexoBrid® in Japan
-
- October 1, 2015
- Kaken Submits a New Drug Application for “KCB-1D”,
Medicinal Product for Periodontal Regeneration
-
- May 12, 2015
- Kaken Announces Change the Trading Unit for Its Common
Stock and Reverse Stock Split
-
- April 1, 2015
- Licensing Agreement for the Development, Manufacturing and Commercialization of BBI-4000
-
- March 15, 2011
- Impact of the Tohoku district-off the Pacific Ocean Earthquake
-
- November 13, 2009
- License Agreement for bFGF in Wound Healing Applications in Europe and North America
-
- July 4, 2007
- Licensing Agreement for the Development, Manufacturing and Marketing of Alpha-9 Antibodies
-
- June 19, 2007
- Kaken and Sunstar to sign a License Agreement for Dental Applications of bFGF in North America and Europe
-
- December 20, 2005
- Kaken licenses out Fiblast® Spray in China
-
- March 14, 2005
- Kaken Obtains Worldwide Rights to bFGF
-
- February 23, 2005
- Kaken to launch “GHRP Kaken 100 Injection” for Diagnosis of Growth Hormone Deficiency
-
- July 7, 2004
- Kaken Launches the Benzylamine Anti-tinea Drug Mentax Spray
-
- April 27, 2004
- Kaken Pharmaceutical and Taiyo Yakuhin Enter into an Exclusive Agreement for Marketing of Prink Injection Syringe, an Alprostadil Preparation in Pre-filled Syringe
-
- April 24, 2003
- KAKEN Pharmaceutical to Increase Year-end Dividend for the 83rd Fiscal Year Ended March 2003
-
- April 10, 2003
- 7th Journal of Pharmaceutical Science and Technology, Japan Prize for the Most Outstanding Thesis Goes to Kaken Pharmaceutical’s Researchers
-
- March 24, 2003
- Kaken to outsource the West Japan Distribution Center
-
- February 20, 2003
- KAKEN PHARMACEUTICAL CO. and ELITRA PHARMACEUTICALS announce antifungal drug discovery and development collaboration
-
- December 16, 2002
- GlaxoSmithKline and Kaken Pharmaceutical To co-promote Zyloric® Tablets 50/100
-
- August 9, 2002
- “Fiblast Spray” to Be Launched in Korea
-
- March 26, 2002
- KAKEN PHARMACEUTICAL Start Operations of Post-marketing Safety Information Management System
-
- February 8, 2002
- Mentax to Be Launched in the US as OTC Drug for Athlete’s Foot
-
- December 17, 2001
- Pharmacia and KAKEN Revise Copromotion Agreement for Cytotec, a Drug for NSAID-induced Ulcers
-
- September 7, 2001
- KAKEN Obtains ISO14001 Certificate for Its Shizuoka Site
-
- February 21, 2001
- Launching of “MIROL Ophth. Soln. 0.5%”, a Long-acting Eye Drop for Glaucoma and Ocular Hypertension
-
- December 14, 2000
- KAKEN PHARMACEUTICAL CO., LTD. and the Institute for Diabetes Discovery, L.L.C. Announce Joint Drug Discovery Program for Insulin Resistance in Type II Diabetes
-
- December 7, 2000
- N.K.Curex and KAKEN to Tie up for Marketing of Diabetic Neuropathy Treatment Aldos
-
- August 3, 2000
- Agreement regarding the sales of Mirol Eye Drop 0.5% with Kyorin Pharmaceutical
-
- February 24, 2000
- Daiichi Pharmaceutical Transfers Manufacturing Rights for Norinyl T28 Contraceptive to KAKEN PHARMACEUTICAL
-
- November 25, 1999
- Ebrantil became the first α１-blocker approved for neurogenic dysuria in the world
-
- October 27, 1999
- Toray and KAKEN PHARMACEUTICAL Solidify Relationship through Stock Swap
-
- September 21, 1999
- KAKEN to close Shiga Factory, Transfer Functions to Shizuoka Factory
-
- August 30, 1999
- Launching of Noriyl T28 (Low-dose Oral Contraceptive)
-
- December 16, 1998
- Arthrotec in-licensing agreement with G.D.Searle
-
- February 24, 1997
- Sales Contract With Genzyme Finalized: Antipostoperative Adhesion Agent “Seprafilm” to Be Marketed by KAKEN
-
- November 13, 1996
- Antifungal Agent “Mentax” ( Butenafine HCl ) Approved by FDA
-
- July 25, 1996
- Application Made for Intractable Skin Ulcer Medication “Fiblast”
